PMC3150201_01
Representative blood glucose profiles before treatment. Blood glucose profile and the dose of each insulin injection are shown (a). The duration between ticks on the X-axis represents 24 h. The frequency of hypoglycemia, defined as below 70 mg/dL of blood glucose, is shown (b).
CRIM2011-381203.001.jpg
PMC3150201_01_CRIM2011-381203.001.jpg
fig1
Representative blood glucose profiles are shown in Figure 1(a), and the frequency of hypoglycemia is shown in Figure 1(b).
The result of the fasting test. Blood glucose levels were monitored. After 17 h of fasting, the blood glucose level decreased to 45 mg/dL.
CRIM2011-381203.002.jpg
PMC3150201_01_CRIM2011-381203.002.jpg
fig2
The result of a fasting test was positive (Figure 2).
Results of SACI tests at 2004 (a) and 2008 (b). A vascular catheter was located to each specific artery (  splenic (distal),   splenic (proximal),   gastroduodenal,   supramesenteric,   proper hepatic,   inferior pancreaticoduodenal artery). Blood samples were collected from the hepatic vein for measuring insulin concentrations before and after stimulation by calcium gluconate (Ca2+ 0.025 mEq/Kg).
CRIM2011-381203.003.jpg
PMC3150201_01_CRIM2011-381203.003.jpg
fig3
The results, confirmed twice, were positive only after stimulations of the supramesenteric artery (SMA) (2.53-fold increase in 2004 and 3.36 in 2008 versus before stimulation; Figures 3(a) and 3(b), resp.).
The effects of a single dose of octreotide (50 mug) on blood glucose and serum immunoreactive insulin levels.
CRIM2011-381203.004.jpg
PMC3150201_01_CRIM2011-381203.004.jpg
fig4
At first, we tried a single dose (50 mug) of octreotide to evaluate its effects on serum insulin and glucose levels (Figure 4).
Representative blood glucose profiles after the treatment of octreotide LAR for 4 months. Blood glucose profile and the dose of each insulin injection are shown (a). The duration between ticks on the X-axis represents 24 h. The frequency of hypoglycemia, defined as below 70 mg/dL of blood glucose, is shown (b).
CRIM2011-381203.005.jpg
PMC3150201_01_CRIM2011-381203.005.jpg
fig5
After using octreotide LAR for 4 months, although hyperglycemia was uncontrollable even with multiple insulin injections (Figure 5(a)), the frequency of hypoglycemic attacks was surprisingly reduced (Figure 5(b)).